On the basis of these observations we decided to make an amendment of our study [21] protocol on dendritic cell-based vaccination in advanced melanoma by adding low-dose TMZ in an attempt to deplete the Foxp3+Treg population. This evidence concerns the gene FOXP3 and melanoma.